Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Clinical Response to T-DM1 in HER2-Amplified, KRAS-Mutated Metastatic Colorectal Cancer.

Journal of the National Comprehensive Cancer Network : JNCCN - 1 Feb 2020

Sandhu Jaideep, Wang Chongkai, Fakih Marwan

Abstract excerpt

HER2 amplification has been identified in 2% to 3% of all colorectal cancers (CRCs). Although the prognostic role of HER2 amplification in metastatic CRC (mCRC) is unclear, studies have highlighted it as a therapeutic target. In addition, several studies have shown that HER2 amplification is implicated in the resistance to EGFR-targeted therapies. Other studies have provided scientific evidence to support the use...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents, Immunological
Share to Antineoplastic Combined Chemotherapy Protocols

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Administration Schedule

Share to Drug Resistance, Neoplasm

Share to Gene Amplification

Share to Proto-Oncogene Proteins p21(ras)

Share to Receptor, ErbB-2

Share to Tomography, X-Ray Computed

Source

Identifiers

PMID: 32023524
DOI: 10.6004/jnccn.2019.7371

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Clinical Response to T-DM1 in HER2-Amplified, KRAS-Mutated Metastatic Colorectal Cancer.PMID 32023524Read ↗

HER2 targeted therapy in colorectal cancer: New horizons.Semantic proximity Read ↗

Response to Trastuzumab and Lapatinib in a Metastatic Colorectal Cancer Harboring HER2 Amplification and HER2 S310F Mutation.Semantic proximity Read ↗

Sequential HER2 blockade as effective therapy in chemorefractory, HER2 gene-amplified, RAS wild-type, metastatic colorectal cancer: learning from a clinical caseSemantic proximity Read ↗

Molecular characterization of ERBB2-amplified colorectal cancer identifies potential mechanisms of resistance to targeted therapies: a report of two instructive cases.Semantic proximity Read ↗

Heterogeneous clinical and pathological landscapes of HER2 positive colorectal cancer.Semantic proximity Read ↗

HER2 in Metastatic Colorectal Cancer: Pathology, Somatic Alterations, and Perspectives for Novel Therapeutic SchemesSemantic proximity Read ↗

Updates in the Treatment of Metastatic Colorectal CancerSemantic proximity Read ↗

Targeting HER2 in colorectal cancer: The landscape of amplification and short variant mutations in ERBB2 and ERBB3.Semantic proximity Read ↗

An anti-EGFR antibody-drug conjugate overcomes resistance to HER2-targeted drugsSemantic proximity Read ↗

Effects of Ado-Trastuzumab Emtansine and Fam-Trastuzumab Deruxtecan on Metastatic Breast Cancer Harboring HER2 Amplification and the L755S Mutation.Semantic proximity Read ↗

HER2 in Colorectal Carcinoma: Are We There yet?Semantic proximity Read ↗

Higher frequency of subclonal anti-EGFR resistance mutations in post-treatment samples from patients with colorectal cancer liver metastases following anti-EGFR-based conversion chemotherapy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.